Genetic disorders of potassium homeostasis

Seminars in Nephrology

Volumn 33, Issue 3, 2013, Pages 300-309

  Jain, Gaurav ^a   Ong, Song ^a   Warnock, David G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Aldosteronism; Bartter; Genetic disorders of potassium; Gitelman; Liddle

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; AMILORIDE; EPLERENONE; GLUCOCORTICOID; POTASSIUM; SODIUM CHLORIDE COTRANSPORTER; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BARTTER SYNDROME; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; DIET SUPPLEMENTATION; FAMILIAL HYPERKALEMIC HYPERTENSION; GENE; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE; GITELMAN SYNDROME; GORDON SYNDROME; HEREDITARY HYPERTENSION; HOMEOSTASIS; HSD11B2 GENE; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPOALDOSTERONISM; HYPOKALEMIA; KIDNEY DISEASE; LIDDLE SYNDROME; MATERNAL HYPERTENSION; POTASSIUM HOMEOSTASIS; PRIORITY JOURNAL; PSEUDOHYPOALDOSTERONISM; RENAL POTASSIUM WASTING DISORDER; SALT WASTING; SLC12A3 GENE; SODIUM RESTRICTION; STEROID 21 MONOOXYGENASE DEFICIENCY;

ALDOSTERONISM; BARTTER; GENETIC DISORDERS OF POTASSIUM; GITELMAN; LIDDLE;

ADRENAL HYPERPLASIA, CONGENITAL; BARTTER SYNDROME; GITELMAN SYNDROME; HUMANS; HYPERALDOSTERONISM; HYPERKALEMIA; HYPOALDOSTERONISM; HYPOKALEMIA; LIDDLE SYNDROME; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; POTASSIUM; PSEUDOHYPOALDOSTERONISM;

EID: 84881587344     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.04.010     Document Type: Article

References (61)

1. Botero-Velez M., Curtis J.J., Warnock D.G. Brief report: Liddle's syndrome revisited--a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 330:178-181.
2. + channel. Cell 1995, 83:969-978.
3. + channel surface expression and proteolytic cleavage. Proc Natl Acad Sci U S A 2006, 103:2805-2808.
4. 2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005, 115:1651-1658.
5. Warnock D.G. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int 1998, 53:18-24.
6. Geller D.S. A mineralocorticoid receptor mutation causing human hypertension. Curr Opin Nephrol Hypertens 2001, 10:661-665.
7. 2+. Annu Rev Physiol 2002, 64:845-876.
8. Sutherland D.J., Ruse J.L., Laidlaw J.C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966, 95:1109-1119.
9. Lifton R.P., et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
10. Fallo F., et al. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004, 18:47-51.
11. Mulatero P., et al. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. J Clin Endocrinol Metab 2002, 87:3187-3191.
12. Jamieson A., et al. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci (Lond) 1995, 88:563-570.
13. Fardella C.E., et al. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001, 86:4805-4807.
14. Vonend O., et al. A German family with glucocorticoid-remediable aldosteronism. Nephrol Dial Transplant 2007, 22:1123-1130.
15. Geller D.S., et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008, 93:3117-3123.
16. Morineau G., et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol 2006, 17:3176-3184.
17. Ulick S., et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979, 49:757-764.
18. Farese R.V., et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991, 325:1223-1227.
19. Wilson F.H., et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-1112.
20. Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med.1998;339:1787-8.
21. Bartter F.C., et al. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 1962, 33:811-828.
22. Birkenhager R., et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001, 29:310-314.
23. Schlingmann K.P., et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 2004, 350:1314-1319.
24. Simon D.B., et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 1997, 17:171-178.
25. Simon D.B., et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996, 13:183-188.
26. + channel, ROMK. Nat Genet 1996, 14:152-156.
27. Vargas-Poussou R., et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 2002, 13:2259-2266.
28. Watanabe S., et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002, 360:692-694.
29. Peters M., et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002, 112:183-190.
30. Jeck N., et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 2001, 108:E5.
31. Colussi G., et al. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol 2007, 2:454-460.
32. Rodriguez-Soriano J., et al. Renal handling of water and sodium in infancy and childhood: a study using clearance methods during hypotonic saline diuresis. Kidney Int 1981, 20:700-704.
33. Sassen M.C., Jeck N., Klaus G. Can renal tubular hypokalemic disorders be accurately diagnosed on the basis of the diuretic response to thiazide?. Nat Clin Pract Nephrol 2007, 3:528-529.
34. Mackie F.E., et al. Neonatal Bartter syndrome--use of indomethacin in the newborn period and prevention of growth failure. Pediatr Nephrol 1996, 10:756-758.
35. Jeck N., et al. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res 2000, 48:754-758.
36. Simon D.B., et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996, 12:24-30.
37. Zelikovic I., et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int 2003, 63:24-32.
38. Cruz D.N., et al. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001, 59:710-717.
39. Colussi G., et al. Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. Am J Nephrol 1994, 14:127-135.
40. Cheek D.B., Perry J.W. A salt wasting syndrome in infancy. Arch Dis Child 1958, 33:252-256.
41. Kerem E., et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999, 341:156-162.
42. Belot A., et al. Pseudohypoaldosteronisms, report on a 10-patient series. Nephrol Dial Transplant 2008, 23:1636-1641.
43. Urbatsch A., Paller A.S. Pustular miliaria rubra: a specific cutaneous finding of type I pseudohypoaldosteronism. Pediatr Dermatol 2002, 19:317-319.
44. Bonny O., Rossier B.C. Disturbances of Na/K balance: pseudohypoaldosteronism revisited. J Am Soc Nephrol 2002, 13:2399-2414.
45. Chang S.S., et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996, 12:248-253.
46. Guran T., et al. Critical points in the management of pseudohypoaldosteronism type 1. J Clin Res Pediatr Endocrinol 2011, 3:98-100.
47. Geller D.S., et al. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 2006, 17:1429-1436.
48. Pujo L., et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat 2007, 28:33-40.
49. Disse-Nicodeme S., et al. Familial hyperkalemic hypertension (Gordon syndrome): evidence for phenotypic variability in a study of 7 families. Adv Nephrol Necker Hosp 2001, 31:55-68.
50. Gordon R.D. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 1986, 8:93-102.
51. Paver W.K., Pauline G.J. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 1964, 2:305-306.
52. Gordon R.D., et al. A new Australian kindred with the syndrome of hypertension and hyperkalaemia has dysregulation of atrial natriuretic factor. J Hypertens Suppl 1988, 6:S323-S326.
53. Gordon R.D., et al. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970, 19:287-294.
54. Schambelan M., Sebastian A., Rector F.C. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 1981, 19:716-727.
55. Yang C.L., et al. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003, 111:1039-1045.
56. Boyden L.M., et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012, 482:98-102.
57. Louis-Dit-Picard H., et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 2012, 44:456-460.
58. White P.C. Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol 2004, 217:81-87.
59. Mitsuuchi Y., et al. Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 1993, 190:864-869.
60. Ulick S. Diagnosis and nomenclature of the disorders of the terminal portion of the aldosterone biosynthetic pathway. J Clin Endocrinol Metab 1976, 43:92-96.
61. Forest M.G. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004, 10:469-485.